US Stock Market Closed

Dashboard

Minerva Neurosciences, Inc. (NERV)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

H

Management & Equity
Analyst Opinion

B

Leverage & Liquidity

H

Fundamental Variables

Rating Performance

FV Performance

About

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301. The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Cambridge, MA.

CEO

Rémy Luthringer

Employees

13

Industry

-

Sector

-

Headquarters

Waltham

Exchange

NASDAQ

Summary Stats

Market Cap

16.7M

Revenue

-

Net Income

-

EPS

$0.00

Price-to-Earnings

-

Price-to-Book

-

Debt-to-Equity

-

News

Analyst Ratings

Price targets projected by 5 analysts

High

$10.00

Average

$6.90

Low

$3.00

Ratings calculated by 6 analysts

Buy

4

Hold

2

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q1 2022

Last Earnings

Missed by -$0.05

Actual

-$0.23 -27.8%

Consensus

-0.18

Report Date

Year Ago

-0.21

Year Ago Change %

Down 9%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites